Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Group Assignment | Adults with health check-ups at multiple health examination centers across China |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fibrotouch | Diagnostic Test | Fibrotouch will be performed showing the stiffness and fat content of liver |
|
| Measure | Description | Time Frame |
|---|---|---|
| To investigate the prevalence of MAFLD among adults at multiple health examination centers across China. | MAFLD means metabolic dysfunction-associated fatty liver disease | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²). | MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index | through study completion, an average of 1 year |
| To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
adults with health check-ups at multiple health examination centers across China.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lai Wei, MD | Contact | +86-010-56119511 | weelai@163.com | |
| Ming Yang, MD | Contact | +86-010-56119512 | ymicecream@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bejing Tsinghua Chang Gung Hospital | Recruiting | Beijing | Bejing | 100034 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26707365 | Background | Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. | |
| 32278004 | Background | Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Jarvinen H, Fan JG, Gronbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8. |
Not provided
Not provided
Not yet determined
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D065626 | Non-alcoholic Fatty Liver Disease |
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index |
| through study completion, an average of 1 year |
| To assess the prevalence of type 2 diabetes among patients with MAFLD. | MAFLD means metabolic dysfunction-associated fatty liver disease | through study completion, an average of 1 year |
| To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD. | MAFLD means metabolic dysfunction-associated fatty liver disease | through study completion, an average of 1 year |